share_log
Breakings ·  Oct 4 04:15
Summit Therapeutics Announces Completion of Enrollment in Its Phase III Harmoni Trial in 2L+ Egfrm Nsclc
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment